# OnCo record b-dormancy-mrd (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-dormancy-mrd/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-dormancy-mrd" ;
  schema:name "Dormant cells and minimal residual disease"@en ;
  schema:description "After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them."@en ;
  schema:url <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2200075>, <https://doi.org/10.1056/NEJMoa1701830>, <https://doi.org/10.1038/s41568-020-0263-0> ;
  onco:related <https://onco.cc/ideas/idea-late-recurrence-interception/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/>, <https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/>, <https://onco.cc/ideas/idea-ctdna-escalation-tnbc/>, <https://onco.cc/ideas/idea-bio2-dormancy-selective-screen/>, <https://onco.cc/ideas/idea-bio2-autophagy-block-mrd/>, <https://onco.cc/ideas/idea-bio2-pro-dormancy-therapy/>, <https://onco.cc/ideas/idea-bio2-il1-awakening-blockade/>, <https://onco.cc/ideas/idea-bio2-national-mrd-platform/>, <https://onco.cc/ideas/idea-bio2-mrd-reference-standards/>, <https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/>, <https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/>, <https://onco.cc/ideas/idea-bio2-whole-genome-mrd-depth/>, <https://onco.cc/ideas/idea-bio2-marrow-niche-on-chip/>, <https://onco.cc/ideas/idea-bio2-localise-the-mrd/>, <https://onco.cc/ideas/idea-bio2-circadian-mrd-sampling/>, <https://onco.cc/ideas/idea-bio2-mrd-guided-endocrine-duration/>, <https://onco.cc/ideas/idea-bio2-mrd-clinic-service/>, <https://onco.cc/ideas/idea-bio2-survivor-plasma-biobank/>, <https://onco.cc/ideas/idea-moon-engineered-immune-surveillance/>, <https://onco.cc/ideas/idea-moon-mrd-weather-service/>, <https://onco.cc/ideas/idea-moon-dormancy-eradication-programme/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:drugs <https://onco.cc/drugs/signatera/> ;
  onco:companies <https://onco.cc/companies/natera/>, <https://onco.cc/companies/foresight-diagnostics/>, <https://onco.cc/companies/adaptive-biotechnologies/>, <https://onco.cc/companies/guardant-health/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/late-recurrence/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/natalee/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-phan-nat-rev-cancer/>, <https://onco.cc/key-papers/paper-pan-n-engl-j-med/> .